B. Riley Wealth Advisors Inc. Sells 370 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

B. Riley Wealth Advisors Inc. lowered its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 34.1% in the third quarter, Holdings Channel reports. The firm owned 716 shares of the biopharmaceutical company’s stock after selling 370 shares during the quarter. B. Riley Wealth Advisors Inc.’s holdings in Regeneron Pharmaceuticals were worth $739,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. International Assets Investment Management LLC lifted its stake in Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after acquiring an additional 879,916 shares during the last quarter. Worldquant Millennium Advisors LLC bought a new position in Regeneron Pharmaceuticals during the third quarter worth about $127,489,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in Regeneron Pharmaceuticals by 23.8% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company’s stock worth $525,804,000 after purchasing an additional 96,266 shares during the period. TD Asset Management Inc increased its position in Regeneron Pharmaceuticals by 30.4% during the second quarter. TD Asset Management Inc now owns 351,545 shares of the biopharmaceutical company’s stock worth $369,484,000 after buying an additional 82,034 shares during the last quarter. Finally, Icon Wealth Advisors LLC raised its stake in Regeneron Pharmaceuticals by 18,342.0% in the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock valued at $79,874,000 after buying an additional 75,569 shares during the period. Institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Truist Financial reduced their target price on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Citigroup initiated coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, November 14th. They issued a “neutral” rating and a $895.00 price objective on the stock. Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price objective on the stock. Evercore ISI reduced their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Finally, Wells Fargo & Company lowered their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a report on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $1,052.90.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $714.62 on Thursday. The company’s 50-day moving average price is $833.09 and its two-hundred day moving average price is $998.86. The firm has a market cap of $78.53 billion, a P/E ratio of 17.68, a P/E/G ratio of 2.19 and a beta of 0.08. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $712.30 and a 12 month high of $1,211.20.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.